Clinical efficacy of cefepime in treating acute infection after chemotherapy

Abstract

Objective To study the efficacy and adverse reactions of different kinds of antibiotics in the treatment of patients with acute leukemia after chemotherapy. Methods 112 cases with acute leukemia after chemotherapy and infected were selected as the research subjects, and were randomly divided into the study group and the control group, 56 cases in each group, Two groups of patients were intravenously injected amikacin sulfate, control group was intravenously injected ceftazidime and study group was given cefepime, two groups of patients were treated for 7 days.The clinical efficacy, the defervescence time, C-reactive protein (CRP) level, peripheral blood neutrophilic granulocyte (ANA) distribution levels and adverse reactions were observed. Results In the control group, the total effective rate was 83.9%, which of the study group was 94.6%, the difference between the two groups was statistically significant (χ2=4.92, P=0.02). The normal rate of ANC in the study group was significantly higher than the control group (χ2=6.62, P=0.01). The average defervescence time of the control group was (3.9±0.8)d, which of the study group was (2.6±0.8) d, there was significant difference between the two groups (t=8.44, P=0.00); CRP level of the study group after treatment was (21.18±4.07)mg/L, which was significantly lower than (37.27±5.32)mg/L of the control group, with significant difference between the two groups (t=7.71, P=0.00). The incidence rate of adverse reaction of study group was 5.3%, which was significantly lower than 19.6% in the control group, with significant difference between the two groups (χ2=5.22, P=0.02). Conclusion Cefepime in the treatment of acute leukemia chemotherapy after infection has significant curative effect, can improve patients' neutral granulocyte number and adverse reactions are mild, it is worthy of popularization in clinical. Key words: Ceftazidime; Cefepime; Acute leukemia; Neutrophil; Clinical effect